Monte Rosa Therapeutics, Inc. announced that Owen Wallace, Ph.D., the Company?s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 USD | -6.23% | -2.81% | -38.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.76% | 226M | |
+21.94% | 46.93B | |
+37.63% | 39.08B | |
-8.39% | 38.48B | |
+29.83% | 31.01B | |
-13.75% | 26.14B | |
+10.93% | 25.88B | |
+36.18% | 12.53B | |
-6.59% | 11.36B | |
-12.42% | 10.65B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board